ESPE Yearbook of Paediatric Endocrinology

To read the full abstract: Endocrinology. 2018 Feb 1;159(2):1035-1049Placental insufficiency leads to intrauterine growth restriction (IUGR) which in the fetus leads to hypoxemia and hypoglycemia. IUGR fetuses are charaterised by having higher circulating catecholamine concentrations and lower circulating insulin concentrations, as well as impaired glucose stimulated insulin secretion. In cases o...

To read the full abstract: Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6.Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist. This 36-week long randomised, placebo-controlled trial in 348 US adults with biopsy confirmed non-alcoholic steatohepatitis (fibrosis stages 1–3) shows that Resmetirom...

In Brief This phase 3 trial including 966 adults with biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosis were randomly assigned (1:1:1 ratio) to once-daily resmetirom 80 mg or 100 mg or placebo. Resmetirom, both 80 and 100 mg daily, were superior to placebo with respect to NASH resolution and improvement in liver fibrosis.NASH resolution occurred more frequently in patients on 80-mg (25.9%) and 100-mg resmetirom (29.9%) than on placebo (...